Vivos Therapeutics Inc., a medical device and technology company specializing in treatments for sleep-related breathing disorders, released its financial results for the first quarter ended March 31, 2025. The company reported an 8% year-over-year increase in product revenue, reflecting its shift towards a new marketing and distribution model. This change is part of Vivos' strategy to move away from legacy Vivos Integrated Provider $(VIP)$ fee revenue and focus on direct sales of its FDA-cleared obstructive sleep apnea treatments. Operating expenses decreased by 5% to $5.4 million, compared to $5.7 million in the same period a year ago, due to cost-cutting measures in sales, marketing, and general administrative costs. Despite these reductions, the company's net loss for the first quarter increased by 3% to $3.9 million, compared with a net loss of $3.8 million in the first quarter of 2024. Vivos sold 3,736 oral appliance arches in the first quarter of 2025, generating approximately $1.8 million in revenue. This compares to 1,996 arches sold in the same period of 2024, with revenue of $1.7 million. The increased sales volume was, in part, due to a higher number of lower-priced guide sales. The company also highlighted its pending acquisition of The Sleep Center of Nevada, which is a key component of its strategy to build strategic alliances and potentially acquire other sleep-focused medical practices. At the end of the first quarter, Vivos reported cash and cash equivalents of $2.3 million and stockholders' equity of $4.4 million. The company aims to continue this strategic pivot to enhance revenue growth and manage cash burn effectively.